As Candida auris continues to spread across the United States and the world, the Centers for Disease Control and Prevention (CDC) issued an update to a June 2016 clinical alert about the often drug-resistant fungus. This update includes information about new cases and current infection control measures.

As of Aug. 31, CDC has reported 153 clinical cases of C. auris in 10 states, with most cases occurring in New Jersey and New York. Of those, five patients previously were hospitalized in countries where C. auris is known to be transmitted, including India, Pakistan, South Africa, and Venezuela. CDC publishes monthly updates on reported cases on its C. auris website.

CDC encourages providers to consider testing both nonsterile, noninvasive body sites and sterile sites to prevent colonization and transmission of the fungus. Providers also should screen people in close contact with infected patients and carefully monitor patients receiving treatment.

Many cases of C. auris are resistant to antifungal drugs, including fluconazole, and some patients have  developed resistance to echinocandin drugs. The fungus can resist quaternary ammoniumbased disinfectants, so CDC recommends that health care providers consult the Environmental Protection Agency’s list of disinfectants effective against clostridium difficile spores.

Contact Director of Policy Erin O’Malley at eomalley@essentialhospitals.org or 202.585.0127 with questions.